Abstract 3854
Background
The aim of this study is to determine the palliative care needs of cancer patients and to examine the knowledge and expectations of the patients and their families about palliative care.
Methods
The research was conducted as a descriptive study.The sampling has formed 110 patients and 110 patients families who received a treatment between the dates of June- August 2017. The datas were collected for using socio-demographic and palliative care survey and questionnaire form, Palliative Performance Scale and Edmonton Symptom Scale.
Results
80.9% of the patients have received information about the disease. 76.4% of the patients and 60% their families weren’t aware of palliative/supportive care, and 49.1% of the patient/55.5% of the family have been seen worries and expectations for treatment and care. These anxieties of in the patients 46.4% can’t be like former ones and 31.8% have got a pain, while the anxieties of in the patients families 43.6% were losing their patients life and 33.6% is the extension of the treatments period. 63.6% of the families had problems with maintaining their daily work. 25% of the patients defined palliative care as end-of-life care, while others patients defined it as a symptom management and supportive treatment. Expectations of 99.1% the patients and 97.3% of their families were to learn the treatment and care plan; 97.3% of the patients and 80% of the families were to be included and supported in the decisions taken; 97.3% of patients and 97.3 of the families were to be informed about cost of treatment-care; in the treatment process 77.3% of the patients / 85.5% of the families were wants to be supported psychological and, 77.3% of the patients / 50% of the families were want to be supported with receive religious and; 84.5% of the patients / 70% of the families were want to be told the diagnosis.
Conclusions
it has been suggested that patients and their families should be informed about the palliative care, physical, psychosocial, support from the spirütüel direction, while it is proposed to development of tools for determination of their needs and requirements. Key words: Palliative care, Supportive treatment, Cancer, Knowledge and expectation, Patient and patient family.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Özlem Topkaya.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2452 - High proportion of multiple KRAS mutations in circulating tumor DNA and tumor tissue of pancreatic ductal adenocarcinoma
Presenter: Min Kyeong Kim
Session: Poster Display session 3
Resources:
Abstract
3328 - Biological difference of tumor mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs. germline BRCA1/2-mutated advanced gastrointestinal (GI) cancers using cell-free DNA (cfDNA) sequencing analysis in the GOZILA study
Presenter: Yasuyuki Kawamoto
Session: Poster Display session 3
Resources:
Abstract
3022 - Cell-Free DNA to Detect Focal Versus Non-Focal MET Amplification in Metastatic Colorectal Cancer Patients: Combined Analysis from Japan and the United States
Presenter: Mishima Saori
Session: Poster Display session 3
Resources:
Abstract
2833 - Presence of circulating tumor DNA in surgically resected renal cell carcinoma is associated with advanced disease and poor patient prognosis
Presenter: Andres Correa
Session: Poster Display session 3
Resources:
Abstract
1376 - Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (cfDNA) for cancer diagnosis and recurrence-risk assessment in early-stage lung cancer
Presenter: Junghee Lee
Session: Poster Display session 3
Resources:
Abstract
4050 - DEMo: a prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy.
Presenter: Arsela Prelaj
Session: Poster Display session 3
Resources:
Abstract
4727 - Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)
Presenter: Cindy Yang
Session: Poster Display session 3
Resources:
Abstract
3662 - Dynamic changes in whole-genome cell-free DNA (cfDNA) to identify disease progression prior to imaging in advanced solid tumors
Presenter: Andrew Davis
Session: Poster Display session 3
Resources:
Abstract
3817 - Evaluation of Microsatellite Instability Testing Through cell-free DNA sequencing
Presenter: Shile Zhang
Session: Poster Display session 3
Resources:
Abstract
3664 - Longitudinal changes in cell-free DNA (cfDNA) methylation levels identify early non-responders to treatment in advanced solid tumors
Presenter: Andrew Davis
Session: Poster Display session 3
Resources:
Abstract